TERN
Terns Pharmaceuticals, Inc.NASDAQHealthcare$52.72-0.13%ClosedMarket Cap: $4.75B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.89
P/S
0.00
EV/EBITDA
-38.42
DCF Value
$5.60
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.0%
ROA
-9.4%
ROIC
-10.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-27.6M | $-23.6M | $-0.24 | — |
| FY 2025 | $0.00 | NaN% | $-110.1M | $-96.2M | $-1.03 | — |
| Q3 2025 | $0.00 | NaN% | $-27.7M | $-24.6M | $-0.27 | — |
| Q2 2025 | $0.00 | -Infinity% | $-27.4M | $-24.1M | $-0.26 | — |
| Q1 2025 | $0.00 | NaN% | $-27.4M | $-23.9M | $-0.26 | — |
| Q4 2024 | $0.00 | NaN% | $-25.9M | $-21.8M | $-0.24 | — |
| FY 2024 | $0.00 | NaN% | $-101.9M | $-88.9M | $-1.12 | — |
| Q3 2024 | $0.00 | NaN% | $-24.9M | $-21.9M | $-0.28 | — |
| Q2 2024 | $0.00 | NaN% | $-25.5M | $-22.7M | $-0.31 | — |
| Q1 2024 | $0.00 | NaN% | $-25.4M | $-22.4M | $-0.30 | — |
| Q4 2023 | $0.00 | NaN% | $-24.1M | $-21.0M | $-0.29 | — |
| FY 2023 | $0.00 | NaN% | $-102.6M | $-90.2M | $-1.27 | — |